[1]
Smith TJ,Johnson JL,Habtewold A,Burmeister MA, Cardiovascular Risk Reduction: A Pharmacotherapeutic Update for Antiplatelet Medications. Critical care nursing clinics of North America. 2019 Mar; [PubMed PMID: 30736932]
[2]
Raimondi P,Hylek EM,Aronis KN, Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies. Current pharmaceutical design. 2017; [PubMed PMID: 27917717]
[5]
Gummin DD,Mowry JB,Spyker DA,Brooks DE,Osterthaler KM,Banner W, 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clinical toxicology (Philadelphia, Pa.). 2018 Dec; [PubMed PMID: 30576252]
[6]
Levine M,Beuhler MC,Pizon A,Cantrel FL,Spyres MB,LoVecchio F,Skolnik AB,Brooks DE, Assessing Bleeding Risk in Patients With Intentional Overdoses of Novel Antiplatelet and Anticoagulant Medications. Annals of emergency medicine. 2018 Mar; [PubMed PMID: 29032872]
[7]
Dornbos D 3rd,Nimjee SM, Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics. Neurosurgery clinics of North America. 2018 Oct; [PubMed PMID: 30223966]
[8]
Teng R,Butler K, Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. European journal of clinical pharmacology. 2010 May; [PubMed PMID: 20091161]
[10]
Needs CJ,Brooks PM, Clinical pharmacokinetics of the salicylates. Clinical pharmacokinetics. 1985 Mar-Apr; [PubMed PMID: 3888490]
[11]
Mehta SR,Tanguay JF,Eikelboom JW,Jolly SS,Joyner CD,Granger CB,Faxon DP,Rupprecht HJ,Budaj A,Avezum A,Widimsky P,Steg PG,Bassand JP,Montalescot G,Macaya C,Di Pasquale G,Niemela K,Ajani AE,White HD,Chrolavicius S,Gao P,Fox KA,Yusuf S, Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (London, England). 2010 Oct 9; [PubMed PMID: 20817281]
[12]
Teng R,Maya J, Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. Journal of drug assessment. 2014; [PubMed PMID: 27536453]
[13]
Zhang YJ,Li MP,Tang J,Chen XP, Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. International journal of environmental research and public health. 2017 Mar 14; [PubMed PMID: 28335443]
[14]
Kim HS,Lim Y,Oh M,Ghim JL,Kim EY,Kim DH,Shin JG, The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. British journal of clinical pharmacology. 2016 Feb; [PubMed PMID: 26426352]
[15]
Nielsen-Kudsk F,Pedersen AK, Pharmacokinetics of dipyridamole. Acta pharmacologica et toxicologica. 1979 May; [PubMed PMID: 474151]
[16]
Bjornsson TD,Mahony C, Clinical pharmacokinetics of dipyridamole. Thrombosis research. Supplement. 1983; [PubMed PMID: 6579711]
[17]
Bramer SL,Forbes WP,Mallikaarjun S, Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clinical pharmacokinetics. 1999; [PubMed PMID: 10702882]
[18]
Schrör K,Weber AA, Comparative pharmacology of GP IIb/IIIa antagonists. Journal of thrombosis and thrombolysis. 2003 Apr; [PubMed PMID: 14618072]
[19]
Sukul D,Seth M,Schreiber T,Hanzel G,Khandelwal A,Cannon LA,Lalonde TA,Gurm HS, The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of interventional cardiology. 2017 Aug; [PubMed PMID: 28543770]
[20]
Bashawri LA,Ahmed MA, The approach to a patient with a bleeding disorder: for the primary care physician. Journal of family [PubMed PMID: 23012146]
[21]
Orme R,Judge HM,Storey RF, Monitoring Antiplatelet Therapy. Seminars in thrombosis and hemostasis. 2017 Apr; [PubMed PMID: 28264200]
[22]
Zhou H,Chen L,He H, Intraoperative and postoperative effects of TEG-guided platelet transfusion on antiplatelet drug-related intracerebral hemorrhage patients. Experimental and therapeutic medicine. 2019 Mar; [PubMed PMID: 30783485]
[23]
Lam H,Katyal N,Parker C,Natteru P,Nattanamai P,Newey CR,Kraus CK, Thromboelastography With Platelet Mapping is Not an Effective Measure of Platelet Inhibition in Patients With Spontaneous Intracerebral Hemorrhage on Antiplatelet Therapy. Cureus. 2018 Apr 22; [PubMed PMID: 29942718]
[24]
Romem R,Tanne D,Geva D,Einhorn-Cohen M,Shlomo N,Bar-Yehuda S,Harnof S, Antithrombotic Treatment Prior to Intracerebral Hemorrhage: Analysis in the National Acute Stroke Israeli Registry. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2018 Nov; [PubMed PMID: 30205997]